## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

DEX0489US.NP

Inventors:

Duan et al.

Serial No.:

10/558,543

Filing Date:

October 23, 2006

Examiner:

Aeder, Sean E.

Customer No.:

32800

Group Art Unit:

1642

Confirmation No.:

6173

Title:

Cln101 Antibody Compositions and Methods of Use Alone and in Combination with

Prostate Specific Antigen and Other

Cancer Markers

**Electronically Submitted via EFS-Web** 

Date: April 22, 2008

I hereby certify that this paper is being electronically submitted on the date indicated above to the Commissioner for Patents, U.S. Patent &

Trademark Office

Typed Name: Kathleen A. Tyrrell, Reg. No. 38,350

Commissioner for Patents

U.S. Patent and Trademark Office

Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- ( ) In accordance with §1.97(b), since this Information
  Disclosure Statement is being filed either within three
  months of the filing date of the above-identified
  application, within three months of the date of entry into
  the national stage of the above identified application as
  set forth in §1.491, or before the mailing date of a first
  Office Action on the merits of the above-identified
  application, no additional fee is required.
- (XX) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
  - ( ) Certification in Accordance with §1.97(e) is attached hereto; or
  - (XX) Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in \$1.17(p) is provided.
- ( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith. Pages 553-555, 557, 559-563, 565-587 and 589-592 are provided for Reference BN.

( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_\_, filed \_\_\_\_\_\_\_, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

(XX) All listed references are in the English language.

Respectfully submitted,

Kathleen A. Tyrrell

Registration No. 38,350

Date: <u>April 22, 2008</u>

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053

(856) 810-1515